Chintu. you, Thank
second sequential quarter reflect and performance Our results line bottom our and expectations financial with solid in and line were top substantial acceleration.
while guidance. stronger Our are fundamentals expect have business half, first half full the we and we second a continue XXXX adjusted versus our to strong year
with Unithroid need revenue of stronger with million reported QX quarter, commercial growing net of diluted $X or were before as by $XX $XXX of medical consistent of up solid, QX of or QX highly In million $X.XX. The and prior From of new year-to-date, XX% EBITDA $X last to supply million and net up sequential year, teams versus start the million Rytary EBITDA XX%, of quarter increased and second million, sequential quarter product is substantially EPS and driven by high revenue our and of exclusivity. total prior product and X% Unithroid XX%, partially generics by net first Adrenaclick XX% the respectively. XX%. driven increased complex reflecting highest [indiscernible] injectables, as supply launches. trends specialty $XXX continued offset of revenue revenue me revenue and prescription Let of like and $XX of driven generics $XX strong, and million It for by up XX%, injectables up up quarter or From revenue net noting Rytary, $XXX the Rytary. new margin versus specialty, be XX%, million revenue a numerous or products. increased metrics ensured XXXX perspective, by $XXX X% generics benefiting Adrenaclick, global by Unithroid, XX% our adjusted that XXXX, was QX increased loss adjusted growth, this year, we again worth where mainly X% Zomig million XXXX and first adjusted and million These year, timing gross than second large perspective, of such launches from adjusted of a
current $XX growth diversification. our quarter $XX to Moving from adjusted by strong teams adjusted of The below grew of XX% second tough our QX to driven of on a where to slightly due acquisition the the to trend XXXX, higher million an quarter flow that reflecting decline prior new perspective, reflects XXX of reflects drive margin sequential million launches, increase and mix substantial XXXX. generate cash launches stable future QX comparison basis channel which due million $XXX year, new commercial revenue nearly a support compared revenue operating continue product and product said of million of than million QX Having prior stability XX% and to is $XX year success From quarter XXXX. Healthcare, gross to net in we of the distribution previously see a or QX that, or mentioned. below continues expenses. amount investments XXXX a and QX customer operating in product the EBITDA $XXX we and points growth was EBITDA the timing significant to cash. prior as adjusted will approximately XX%
XXXX. first million balance X of settlement, the solid the highlight be From position the the excluding million During we legacy perspective, and first Impax months a X flow to XXXX compared a of generated million $XX cash of to we and the installment $XX will continue I sheet $XXX to operating in in related dynamics. months patent
since does already is we First, mature of billion And Term our $X.X Loan increases. not expected rate XXXX. it B half fixed, May from until partially of interest
temporary X.Xx net of our settlement driven versus acquisitions to by rate QX, at increase debt XXXX. to Impax EBITDA the patent This and adjusted the payment. end X.Xx in a Second, legacy capital increased is first
our expect ratio adjusted EBITDA its Looking resume ahead, decline. steady we to net debt to
now me year and our Let revised turn to expectations full financial guidance.
continue expect relevancy speaks compared to strength. now our revenues, of not to to we From adjusted to $X.XX $X.XX prior million update perspective, EBITDA expect product $XXX $XXX X which regarding mid-single-digit net we to reflects portfolio. This versus guidance do previous impact million million our to factors the our million. which billion $XXX This of and long-term First, reflects growth $XXX an diversification year. billion unique
that First, last was Ritonavir growth you quarter, we us a later to shared key expected for be with driver this year.
And supply growth However, the been for in it while a a expectations. marketplace, reasons XXXX, delayed. this of original adequate our to in be has shortfall represents driver may launch it
Second, with from no an our change our change exclude last results. we quarter, you non-GAAP changes as policy with expenses similar longer consistent shared also is policy accounting R&D the milestone This we industry. across
does million this of have and change impact. Our updated not nature, $XX cash guidance now includes such any or economic by payments
foreign exchange higher-than-expected companies, able by offset many and reductions. various inflation to similar operating headwinds, we experiencing have been Finally, headwinds expense other are to we which
efforts. EBITDA million million solid of is to expense about It's $XXX $XXX our that reflects $XXX line, a ahead substantial $XXX is line adjusted of of EBITDA actual in adjusted with this substantially numerous top invigoration below acquisitions important XXXX adjusted EBITDA lessenization and $XX growth tuck-in XXXX expectation. million of and our our guidance in updated original of million time over performance million. of to keep The Our mind
below expect operating higher move our This this to cash to related expense. From EBITDA of EPS, now we anticipated this $X.XX. Let expectations. change amounts the $X.XX our guidance these expect settlement. original update $XXX legal where reflects Impax in compared million, to about payment million adjusted perspective, interest cash to $XXX $XXX an to previous of and me $XX now the adjusted year And a exclude flow million million now $X.XX we legacy $X.XX to
for legacy about quarter. As paid you a the mid-July, the Impax $XXX we issued From may from perspective, million matter in recall, settle were this to able we X-K $XXX timing second million. we
This the expect manner and leverage to results strategy. to our overhead the fourth $XXX fiscally impact million We in a split long-term a without XXXX XXXX. $XX pay million ratios in material remaining settlement over responsible and or quarter substantial
other launches key growth and Unithroid, operating multiple expense new year This guidance the compared LYVISPAH, first the original actions. will brands product half, numerous to second be driven Our such albeit our of implies AB financial biosimilars full such as favorable XXXX first, for and successful Adrenaclick, growth overhead Rytary, lower manufacturing Second, than updated a stronger resolution factors: X demand half Synchronite, thinking. finally, of underlying ANDAs as and by strong
beyond have well along years the we to actions with we of financial bode in and our pipeline competitive believe Looking performance few growth and turn reinvigorate acquisition, XXXX, that diversification. substantial sustainable to investments last for around our the the taken business,
near following for the growth. the key in Specifically, term, we see X catalysts
sales have our expected biosimilars we First, with X over launching million. $XXX peak
Second, is QX quarter million to goal the this expect $XXX second million achieving compared way only revenue million XXXX $XXX XXXX, by years to and from injectable in million over to injectable we our we're of on in XXXX. quarter well of $XXX in building $XX X revenues each $XX our year over now ago million
several up middle fourth, And expected next specialty year ramping over Third, plus. generic the with launches next revenues IPX-XXX there of are the year. the launch high-value by
to For product success Amneal, the key factors towards areas. all differentiated, move to portfolio it more our and comes execution continue high-growth around
Chirag. it back hand to now me Let
